ADC Cell Line Development: Building the Antibody Behind an Antibody-Drug Conjugate
Antibody-drug conjugates remain one of the hottest areas in oncology. As of June 30, 2026, 23 ADCs had regulatory approval worldwide. In addition, China approved izalontamab brengitecan on June 22, 2026, reported as the first approved bispecific ADC. Payloads and linkers get most of the headlines. However, every ADC starts with an antibody made in mammalian cells. That makes ADC cell line development a critical first step.
Why the Antibody Intermediate Matters
The antibody controls targeting, internalization, and circulation time. It also shapes how the payload attaches. Traditional antibody-drug conjugate chemistry links drugs to lysines or to cysteines from reduced interchain disulfides. The resulting drug-to-antibody ratio, or DAR, influences both efficacy and safety. For example, IgG1 has four interchain disulfides. Reducing them yields up to eight cysteines for conventional conjugation.
Consequently, heterogeneity in the antibody can carry into the final conjugate. Charge variants, aggregates, and sequence variants all deserve attention before conjugation.
Site-Specific Conjugation Raises the Bar
Many newer ADCs use site-specific designs to control DAR. For example, some add engineered cysteines. Others rely on glycan remodeling or non-natural amino acids. Each approach changes what a good clone looks like. Non-natural amino acid systems, for instance, require specialized expression machinery. As a result, titers and timelines can differ from a standard antibody program.
Engineered cysteines can pick up unwanted modifications during culture. Similarly, glycan-based conjugation depends on consistent glycosylation. Therefore, clone screening should track the attributes your conjugation chemistry relies on.
ADC Cell Line Development Priorities
First, confirm stable expression across the passage range needed for production. Next, screen for low aggregation and consistent charge profiles. Additionally, verify sequence integrity at conjugation sites. Finally, secure a well-documented master and working cell bank.
Our post on cell banking strategy covers how to size those banks. For warning signs during development, see early risk signals in cell line development.
ADC Cell Line Development and Antibody Supply
Conjugation development can consume more antibody than teams expect. Linker screening, DAR optimization, and stability studies each draw on the same supply. In addition, toxicology and analytical method work need consistent material. Therefore, a productive, stable clone protects both timelines and budgets.
Consistent lots matter as much as volume. For example, switching antibody lots mid-study can confound conjugation results. Our protein production services help teams plan for this demand.
Where Cell Culture Company Fits
Cell Culture Company supports cell line development, cell banking, antibody production, and purification in one facility. As a result, your conjugation partner can receive a well-characterized antibody with clear documentation.
Frequently Asked Questions
What is ADC cell line development?
It is the process of building a stable, productive cell line for the antibody used in an ADC. The best clones also support consistent conjugation and a predictable DAR.
Does antibody quality affect ADC performance?
Yes. Aggregates, charge variants, and sequence changes can alter conjugation and stability. Consequently, antibody quality directly influences the finished conjugate.
